Blockade of constitutively activated Janus kinase/signal transducer and activator of transcription-3 pathway inhibits growth of human pancreatic cancer

Cancer Letters

Volumn 201, Issue 1, 2003, Pages 107-116

  Toyonaga, Takayuki ^a   Nakano, Kenji ^a   Nagano, Masahiro ^a   Zhao, Gang ^a   Yamaguchi, Koji ^a   Kuroki, Syoji ^a   Eguchi, Takashi ^a   Chijiiwa, Kazuo ^b   Tsuneyoshi, Masazumi ^a   Tanaka, Masao ^a  

^a KYUSHU UNIVERSITY   (Japan)

^b UNIVERSITY OF MIYAZAKI   (Japan)

Author keywords

Angiogenesis; Apoptosis resistance; Growth; Janus kinase; Pancreatic cancer; Signal transducer and activator of transcription (Stat) 3

Indexed keywords

ADENOVIRUS VECTOR; CYCLIN D1; JANUS KINASE; MESSENGER RNA; N BENZYL 2 CYANO 3 (3,4 DIHYDROXYPHENYL)ACRYLAMIDE; PROTEIN BCL XL; PROTEIN KINASE INHIBITOR; STAT3 PROTEIN; VASCULOTROPIN;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CANCER CELL CULTURE; CANCER GROWTH; CANCER INHIBITION; CANCER TISSUE; CONTROLLED STUDY; GEL MOBILITY SHIFT ASSAY; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INOCULATION; PANCREAS CANCER; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN FUNCTION; REGULATORY MECHANISM; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION;

ADENOVIRIDAE; JANUS;

EID: 0142122338     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0304-3835(03)00482-8     Document Type: Article

References (24)

1. Gunzburg W.H., Salmons B. Novel clinical strategies for the treatment of pancreatic carcinoma. Trends Mol. Med. 7:2001;30-37.
2. Niederhuber J.E., Brennan M.F., Menck H.R. The National Cancer Data Base report on pancreatic cancer. Cancer. 76:1995;1671-1677.
3. Neoptolemos J.P., Russell R.C., Bramhall S., Theis B. Low mortality following resection for pancreatic and periampullary tumours in 1026 patients: UK survey of specialist pancreatic units. UK Pancreatic Cancer Group. Br. J. Surg. 84:1997;1370-1376.
4. Wade T.P., Halaby I.A., Stapleton D.R., Virgo K.S., Johnson F.E. Population-based analysis of treatment of pancreatic cancer and whipple resection: Department of Defense hospitals, 1989-1994. Surgery. 120:1996;680-685. discussion 686-687.
5. Yeo C.J., Cameron J.L. Pancreatic cancer. Curr. Probl. Surg. 36:1999;59-152.
6. Glimelius B. Chemotherapy in the treatment of cancer of the pancreas. J. Hepatobiliary Pancreat. Surg. 5:1998;235-241.
7. Burris H.A., Moore M.J., Andersen J., Green M.R., Rothenberg M.L., Modiano M.R., Cripps M.C., Portenoy R.K., Storniolo A.M., Tarssoff P., Nelson R., Dorr F.A., Stephens C.D., Von Hoff D.D. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J. Clin. Oncol. 15:1997;2403-2413.
8. Berlin J., Catalano P., Thomas J., Kluger J., Haller D., Benson A.B. A phase III study of gemcitabine in combination with 5-FU vs gemcitabine alone in patients with advanced pancreatic carcinoma (E2297): an Eastern Cooperative Oncology Group (ECOG) trial (abstract). Proc. Am. Soc. Clin. Oncol. 20:2001;505.
9. Kachnic L.A., Shaw J.E., Manning M.A., Lauve A.D., Neifeld J.P. Gemcitabine following radiotherapy with concurrent 5-fluorouracil for nonmetastatic adenocarcinoma of the pancreas. Int. J. Cancer. 96:2001;132-139.
10. Bromberg J., Darnell J.E. Jr. The role of STATs in transcriptional control and their impact on cellular function. Oncogene. 19:2000;2468-2473.
11. Zhang Y.W., Wang L.M., Jove R., Vande Woude G.F. Requirement of Stat3 signaling for HGF/SF-Met mediated tumorigenesis. Oncogene. 21:2002;217-226.
12. Zhong Z., Wen Z., Darnell J.E. Jr. Stat3: a STAT family member activated by tyrosine phosphorylation in response to epidermal growth factor and interleukin-6. Science. 264:1994;95-98.
13. Burke W.M., Jin X., Lin H.J., Huang M., Liu R., Reynolds R.K., Lin J. Inhibition of constitutively active Stat3 suppresses growth of human ovarian and breast cancer cells. Oncogene. 20:2001;7925-7934.
14. Garcia R., Bowman T.L., Niu G., Yu H., Minton S., Muro-Cacho C.A., Cox C.E., Falcone R., Fairclough R., Parsons S., Laudano A., Gazit A., Levitzki A., Kraker A., Jove R. Constitutive activation of Stat3 by the Src and JAK tyrosine kinases participates in growth regulation of human breast carcinoma cells. Oncogene. 20:2001;2499-2513.
15. Gouilleux-Gruart V., Gouilleux F., Desaint C., Claisse J.F., Capiod J.C., Delobel J., Weber-Nordt R., Dusanter-Fourt I., Dreyfus F., Groner B., Prin L. STAT-related transcription factors are constitutively activated in peripheral blood cells from acute leukemia patients. Blood. 87:1996;1692-1697.
16. Masuda M., Suzui M., Yasumatu R., Nakashima T., Kuratomi Y., Azuma K., Tomita K., Komiyama S., Weinstein I.B. Constitutive activation of signal transducers and activators of transcription 3 correlates with cyclin D1 overexpression and may provide a novel prognostic marker in head and neck squamous cell carcinoma. Cancer Res. 62:2002;3351-3355.
17. Ni Z., Lou W., Leman E.S., Gao A.C. Inhibition of constitutively activated Stat3 signaling pathway suppresses growth of prostate cancer cells. Cancer Res. 60:2000;1225-1228.
18. Shouda T., Yoshida T., Hanada T., Wakioka T., Oishi M., Miyoshi K., Komiya S., Kosai K., Hanakawa Y., Hashimoto K., Nagata K., Yoshimura A. Induction of the cytokine signal regulator SOCS3/CIS3 as a therapeutic strategy for treating inflammatory arthritis. J. Clin. Invest. 108:2001;1781-1788.
19. Nakano K., Chijiiwa K., Tanaka M. Lower activity of CCAAT/enhancer- binding protein and expression of cyclin E, but not cyclin D1, activating protein-1 and p21(WAF1), after partial hepatectomy in obstructive jaundice. Biochem. Biophys. Res. Commun. 280:2001;640-645.
20. Hidaka H., Ishiko T., Furuhashi T., Kamohara H., Suzuki S., Miyazaki M., Ikeda O., Mita S., Setoguchi T., Ogawa M. Curcumin inhibits interleukin 8 production and enhances interleukin 8 receptor expression on the cell surface: impact on human pancreatic carcinoma cell growth by autocrine regulation. Cancer. 95:2002;1206-1214.
21. Friess H., Lu Z., Andren-Sandberg A., Berberat P., Zimmermann A., Adler G., Schmid R., Buchler M.W. Moderate activation of the apoptosis inhibitor bcl-xL worsens the prognosis in pancreatic cancer. Ann. Surg. 228:1998;780-787.
22. Itakura J., Ishiwata T., Friess H., Fujii H., Matsumoto Y., Buchler M.W., Korc M. Enhanced expression of vascular endothelial growth factor in human pancreatic cancer correlates with local disease progression. Clin. Cancer Res. 3:1997;1309-1316.
23. Wei D., Le X., Zheng L., Wang L., Frey J.A., Gao A.C., Peng Z., Huang S., Xiong H.Q., Abbruzzese J.L., Xie K. Stat3 activation regulates the expression of vascular endothelial growth factor and human pancreatic cancer angiogenesis and metastasis. Oncogene. 22:2003;319-329.
24. Gansauge S., Gansauge F., Ramadani M., Stobbe H., Rau B., Harada N., Beger H.G. Overexpression of cyclin D1 in human pancreatic carcinoma is associated with poor prognosis. Cancer Res. 57:1997;1634-1637.